サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：組換え血漿タンパク質治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149154

組換え血漿タンパク質治療の世界市場－成長、将来展望、競合分析（2022年～2030年）

Recombinant Plasma Protein Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
組換え血漿タンパク質治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月05日
発行: Acute Market Reports
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の組換え血漿タンパク質治療の市場規模は、2021年の84億3,530万米ドルから、2030年には172億3,107万米ドルに達し、2022年から2030年までのCAGRは8.3%と予測されています。公衆衛生意識の高まり、血友病Aの有病率の上昇、政府が資金援助する血友病治療センターの総合的なネットワークの存在は、組換え血漿タンパク質治療市場の成長を促進しています。

当レポートでは、世界の組換え血漿タンパク質治療市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の組換え血漿タンパク質治療市場
  • 世界の組換え血漿タンパク質治療市場（100万米ドル）（2021年）：薬剤クラス別
  • 世界の組換え血漿タンパク質治療市場（100万米ドル）（2021年）：細胞株別
  • 世界の組換え血漿タンパク質治療市場（100万米ドル）（2021年）：適応症別
  • 世界の組換え血漿タンパク質治療市場（100万米ドル）：地域別
  • COVID-19の影響
  • 魅力的な投資提案（2021年）：地域別
  • 競合分析
    • 主要な組換え血漿タンパク質治療市場ベンダーの市場ポジショニング
    • 組換え血漿タンパク質治療市場のベンダーが採用する戦略
    • 主要な業界戦略

第3章 組換え血漿タンパク質治療市場：ビジネス展望と市場力学

  • イントロダクション
  • 世界の組換え血漿タンパク質治療市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）：薬剤クラス別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • 組換え第Ⅷ因子
    • 組換え第Ⅸ因子

第5章 組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）：細胞株別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • チャイニーズハムスターの卵巣
    • 幼ハムスターの腎臓
    • ヒト胎児の腎臓
    • その他

第6章 組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）：適応症別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • 血友病A
    • 血友病B
    • フォン・ヴィレブランド病
    • その他

第7章 北米の組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）

第8章 英国および欧州連合の組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）

第9章 アジア太平洋の組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）

第10章 ラテンアメリカの組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）

第11章 中東およびアフリカの組換え血漿タンパク質治療市場、米ドル（100万）（2020年～2030年）

第12章 企業プロファイル

  • Aptevo Therapeutics
  • Bayer AG
  • Bioverativ Therapeutics, Inc.
  • CSL Behring
  • Novo Nordisk A/S
  • Octapharma, Plc.
  • Pfizer, Inc.
  • Pharming Group NV
  • Shire, Plc.
  • Viropharma Biologics, Inc.
図表

List of Tables

  • TABLE 1 Global Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 Global Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 3 Global Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
  • TABLE 4 North America Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 North America Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 6 North America Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
  • TABLE 7 UK and European Union Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 UK and European Union Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 9 UK and European Union Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
  • TABLE 10 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 12 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
  • TABLE 13 Latin America Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 Latin America Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 15 Latin America Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
  • TABLE 16 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
  • TABLE 18 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Recombinant Plasma Protein Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Recombinant Plasma Protein Therapeutics Market: Quality Assurance
  • FIG. 5 Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021
  • FIG. 6 Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021
  • FIG. 7 Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021
  • FIG. 8 Global Recombinant Plasma Protein Therapeutics Market, By Geography, 2021
  • FIG. 9 Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 10 Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021 Vs 2030, %
  • FIG. 11 Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021 Vs 2030, %
  • FIG. 12 U.S. Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 13 Canada Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 14 Rest of North America Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 15 UK Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 16 Germany Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 17 Spain Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 18 Italy Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 19 France Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 20 Rest of Europe Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 21 China Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 22 Japan Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 23 India Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 24 Australia Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 25 South Korea Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 26 Rest of Asia Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 27 Brazil Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 28 Mexico Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 29 Rest of Latin America Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 30 GCC Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 31 Africa Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 32 Rest of Middle East and Africa Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
目次
Product Code: 138679-08-22

Industry Outlook

The recombinant plasma protein therapeutics market is set to grow from US$ 8,435.3 Mn in 2021 to US$ 17,231.07 Mn in 2030 expanding at an annual growth rate of 8.3% during the forecast period from 2022 to 2030. According to World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer with some form of bleeding disorder, 75% of them gain inadequate treatment and remain undiagnosed.

Lack of blood borne transmission disease and less severe effects in comparison to desmopressin popularizes recombinant coagulation factor VIII in treating hemophilia A

Recombinant coagulation factor VIII is leading the drug class segment for recombinant plasma protein therapeutics market. It is preferred over human plasma derive products to avoid potential transmission of blood borne infections. It is replacing desmopressin in treating mild hemophilia due to less adverse effects. Recombinant factor IX will gain growth momentum in the near future owing to recent FDA approval of Rebinyn (Novo Nordisk) for long term treatment of hemophilia B.

Ability to adapt growth conditions in serum free suspension, powerful gene amplification system and capacity for post translational modification drive the Chinese hamster ovary cell lines in recombinant protein synthesis

Since last 2 decades Chinese hamster ovarian cell lines have gained immense popularity over other cell lines such as baby hamster kidney cell lines and human embryonic kidney cell lines. Its ability to adapt growth conditions in serum free suspension, powerful gene amplifications and capacity for post translational modification proves its popularity as the most demanding cell line over others in recombinant protein syntheis.

High prevalence rate and 70 % of the diagnosed patients reported to suffer with severe form drive Hemophilia A market growth

Hemophilia A also known as clotting factor VIII deficiency or classical hemophilia is currently leading the indication segment for recombinant plasma protein therapeutics market. It has a high prevalence rate of 1 in 5000 people with approximately 70% diagnosed patients reported to be suffering with severe form of hemophilia A. The other type is Hemophilia B which is less common form with an occurrence rate of 1 in 25,000 people, it is caused due to lack of clotting factor IX. Von Willebrand disease is keen to register impressive growth in the near future due to high occurrence in blood group O type and rising public health awareness.

Rising prevalence of Hemophilia A and presence of a comprehensive network of federally funded treatment centers for hemophilia drive market growth in North America

North America is reigning the regional segment for recombinant plasma protein therapeutics market with a share of 40%. The chief factors controlling its market growth are rising prevalence of hemophilia A, according to the research findings of Center for Disease Control and Prevention (CDC), approximately 20,000 people are suffering with hemophilia in the United States. The existence of a comprehensive network of federally funded treatment centers for hemophilia cater to the medical aid of 70% patients with blood clotting disorders in North America region. Europe accounts for 30% market share due to increasing new born babies suffering with hemophilia. According to European Medical Agency (EMA) research findings annually 400 babies are born with hemophilia. Domicile of major players such as Novo Nordisk A/S, Bayer AG, Shire, Plc etc. bolster the market growth in Europe. Asia Pacific holds 20% market growth and is keen to register rapid growth during the forecast period owing to adoption of recombinant technology for protein synthesis and large patient pool suffering with blood clotting disorders.

Biotechnology companies manufacturing recombinant plasma proteins are: Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Recombinant Plasma Protein Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Recombinant Plasma Protein Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS

  • Research Period: 2020-2030
  • Base Year: 2021
  • Forecast Period: 2022-2030
  • Historical Year: 2020
  • Unit: USD Million

Market Segmentation

Drug Class

  • Recombinant Factor VIII
  • Recombinant Factor IX

Cell Line

  • Chinese Hamster Ovary
  • Baby Hamster Kidney
  • Human Embryonic Kidney
  • Others

Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Recombinant Plasma Protein Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Recombinant Plasma Protein Therapeutics market?
  • Which is the largest regional market for Recombinant Plasma Protein Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Recombinant Plasma Protein Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Recombinant Plasma Protein Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Recombinant Plasma Protein Therapeutics Market
  • 2.2. Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021 (US$ Million)
  • 2.4. Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021 (US$ Million)
  • 2.5. Global Recombinant Plasma Protein Therapeutics Market, By Geography, 2021 (US$ Million)
  • 2.6. Impact of Covid 19
  • 2.7. Attractive Investment Proposition by Geography, 2021
  • 2.8. Competitive Analysis
    • 2.8.1. Market Positioning of Key Recombinant Plasma Protein Therapeutics Market Vendors
    • 2.8.2. Strategies Adopted by Recombinant Plasma Protein Therapeutics Market Vendors
    • 2.8.3. Key Industry Strategies

3. Recombinant Plasma Protein Therapeutics Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Recombinant Plasma Protein Therapeutics Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Recombinant Factor VIII
    • 4.3.2. Recombinant Factor IX

5. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Chinese Hamster Ovary
    • 5.3.2. Baby Hamster Kidney
    • 5.3.3. Human Embryonic Kidney
    • 5.3.4. Others

6. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Hemophilia A
    • 6.3.2. Hemophilia B
    • 6.3.3. Von Willebrand Disease
    • 6.3.4. Others

7. North America Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
  • 7.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
  • 7.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 7.5.1.North America
      • 7.5.1.1. U.S.
      • 7.5.1.2. Canada
      • 7.5.1.3. Rest of North America

8. UK and European Union Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
  • 8.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
  • 8.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 8.5.1.UK and European Union
      • 8.5.1.1. UK
      • 8.5.1.2. Germany
      • 8.5.1.3. Spain
      • 8.5.1.4. Italy
      • 8.5.1.5. France
      • 8.5.1.6. Rest of Europe

9. Asia Pacific Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
  • 9.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
  • 9.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 9.5.1.Asia Pacific
      • 9.5.1.1. China
      • 9.5.1.2. Japan
      • 9.5.1.3. India
      • 9.5.1.4. Australia
      • 9.5.1.5. South Korea
      • 9.5.1.6. Rest of Asia Pacific

10. Latin America Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
  • 10.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
  • 10.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 10.5.1.Latin America
      • 10.5.1.1. Brazil
      • 10.5.1.2. Mexico
      • 10.5.1.3. Rest of Latin America

11. Middle East and Africa Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 11.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
  • 11.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
  • 11.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 11.5.1.Middle East and Africa
      • 11.5.1.1. GCC
      • 11.5.1.2. Africa
      • 11.5.1.3. Rest of Middle East and Africa

12. Company Profile

  • 12.1. Aptevo Therapeutics.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Bayer AG
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Bioverativ Therapeutics, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. CSL Behring
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Novo Nordisk A/S
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Octapharma, Plc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Pharming Group NV
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Shire, Plc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Viropharma Biologics, Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives